News
Circle Pharma, a clinical-stage ... Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung ...
The poster will showcase the design and ongoing progress of its Phase 1 study of CID-078 (NCT06577987), a first-in-class, or. SOUTH SAN FRANCISCO, Calif., May 12, 2025--Circle Pharma, ...
“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback